We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.95B
1-Year Est. Return 773.9%
This Fund
S&P 500
This Quarter Est. Return
+4.81%
1 Year Est. Return
+773.9%
3 Year Est. Return
+3,976.92%
5 Year Est. Return
+17,750.67%
10 Year Est. Return
+592,782.78%
AUM
$603M
AUM Growth
-$85.4M
Cap. Flow
-$61M
Cap. Flow %
-10.11%
Top 10 Hldgs %
45.31%
Holding
86
New
11
Increased
4
Reduced
19
Closed
15

Top Buys

Rank Stock Value
1
BLUE
bluebird bio
BLUE
+$25.6M
2
RXDX
Ignyta, Inc.
RXDX
+$12.2M
3
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$12M
4
OMER icon
Omeros
OMER
+$9.6M
5
GTHX
G1 Therapeutics, Inc. Common Stock
GTHX
+$8.4M

Top Sells

Rank Stock Value
1
TBPH icon
Theravance Biopharma
TBPH
+$18.3M
2
CRBP icon
Corbus Pharmaceuticals
CRBP
+$13.9M
3
FWP
Forward Pharma A/S American Depositary Shares
FWP
+$12.7M
4
ZYNE
Zynerba Pharmaceuticals, Inc
ZYNE
+$10.1M
5
CBPO
China Biologic Products Holdings, Inc.
CBPO
+$10M

Sector Composition

Rank Sector Weight
1 Healthcare 99.63%
2 Miscellaneous 0.37%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABEO icon
51
Abeona Therapeutics
ABEO
$305M
$2.56M 0.42%
16,000
– –
RGNX icon
52
Regenxbio
RGNX
$520M
$2.37M 0.39%
120,000
– –
OVID icon
53
Ovid Therapeutics
OVID
$527M
$2.35M 0.39%
+223,972
New +$2.92M
SCTL
54
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$2.34M 0.39%
371,518
-286,332
-44% -$1.96M
PFNX
55
DELISTED
Pfenex Inc.
PFNX
$2.31M 0.38%
574,966
– –
XLRN
56
DELISTED
Acceleron Pharma
XLRN
$2.28M 0.38%
75,000
– –
ZYME icon
57
Zymeworks
ZYME
$1.87B
$1.94M 0.32%
+232,008
New +$2.6M
XNCR icon
58
Xencor
XNCR
$1.78B
$1.58M 0.26%
75,000
– –
APTO
59
DELISTED
Aptose Biosciences, Inc.
APTO
$1.22M 0.2%
2,201
– –
MYOV
60
DELISTED
Myovant Sciences Ltd.
MYOV
$1.17M 0.19%
100,000
– –
PTLA
61
CALL
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$1.16M 0.19%
+1,000
New +$40.1K
MRSN
62
DELISTED
Mersana Therapeutics
MRSN
$1.11M 0.18%
+3,192
New +$1.1M
OTLK icon
63
Outlook Therapeutics
OTLK
$168M
$1.01M 0.17%
6,266
– –
ABBV icon
64
CALL
AbbVie
ABBV
$465B
$939K 0.16%
+6,100
New +$410K
HTGM
65
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
$541K 0.09%
1,130
– –
NEOS
66
DELISTED
Neos Therapeutics, Inc
NEOS
$369K 0.06%
50,613
– –
MTEM
67
DELISTED
Molecular Templates, Inc.
MTEM
$354K 0.06%
5,455
– –
CLRB icon
68
Cellectar Biosciences
CLRB
$22.4M
$87K 0.01%
18
– –
ONSIW
69
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
$72K 0.01%
416,666
– –
ONSIZ
70
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
$39K 0.01%
416,666
– –
CLRBW
71
DELISTED
Cellectar Biosciences, Inc.
CLRBW
$12K ﹤0.01%
52,999
– –
ASND icon
72
Ascendis Pharma A/S
ASND
$16.2B
– –
-100,000
Closed -$2.8M
CRBP icon
73
Corbus Pharmaceuticals
CRBP
$139M
– –
-56,203
Closed -$13.9M
CRVS icon
74
Corvus Pharmaceuticals
CRVS
$1.05B
– –
-81,000
Closed -$1.68M
CBIO
75
Crescent Biopharma
CBIO
$659M
– –
-2,870
Closed -$1.56M
1 2
3
4

Similar funds

AHC
Adell Harriman & Carpenter Houston, Texas $1.95B AUM 52.72% 1-Year Est. Return
FFS
Founders Financial Securities Towson, Maryland $1.95B AUM 22.17% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.95B AUM 25.88% 1-Year Est. Return
BFPW
BOK Financial Private Wealth Denver, Colorado $1.95B AUM 20.52% 1-Year Est. Return
MSA
MUFG Securities Americas New York $1.95B AUM 42.71% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Cormorant Asset Management's Q2 2017 Portfolio in Review

As of Q2 2017, Cormorant Asset Management held 86 positions worth $603M, down 12% from $689M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Cormorant Asset Management withdrew a net $61M in Q2 2017, closing 15 positions and reducing 19 holdings. Its most notable exit was Corbus Pharmaceuticals, an estimated $13.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Cormorant Asset Management opened a new position in bluebird bio worth $28.9M.

  • Cormorant Asset Management's largest Q2 2017 buy was bluebird bio: 21,230 shares worth $28.9M.
  • Cormorant Asset Management added most to Portola Pharmaceuticals, Inc. in Q2 2017, an estimated $12M increase.
  • Cormorant Asset Management's biggest Q2 2017 reduction was Theravance Biopharma, cutting an estimated $18.3M.
  • Cormorant Asset Management fully exited Corbus Pharmaceuticals in Q2 2017, selling an estimated $13.9M.
  • Cormorant Asset Management's ten largest holdings make up 45% of its $603M portfolio in Q2 2017.
  • Cormorant Asset Management opened 11 new positions and closed 15 in Q2 2017.
  • Cormorant Asset Management's portfolio value fell 12% quarter-over-quarter to $603M.

Based on Cormorant Asset Management's 13F filing for Q2 2017, filed 14 Aug 2017.